NeuroVive Pharmaceutical AB
* NeuroVive completes 10 percent acquisition of Isomerase Therapeutics
* Says now completed acquisition includes approximately 5 percent further of shares in Isomerase through a 550 000 GBP cash payment Source text for Eikon: Further company coverage:
Recent Articles on M&A
Source: Reuters.com
